Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixovex-1 +/- Pembrolizumab in Solid Tumours
NCT06549946Phase 2Recruiting
- Sponsor
- PsiVac Ltd
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label trial of Ixovex-1 in solid tumor, head and neck cancer (HNC) and cutaneous squamous cell carcinoma (cSCC) (3 arms), sponsored by PsiVac Ltd. Primary endpoints: Safety profile of Ixovex-1 alone or in combination with Pembrolizumab at 2 years and Maximum Tolerated Dose and Recommended Phase 2 Dose at 2 years. Started Dec 2024; status: recruiting.
02
Drugs
Ixovex-1
03
Conditions
solid tumorhead and neck cancer (HNC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06549946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549946.